IL141126A0 - Herpes virus vectors for dendritic cells - Google Patents

Herpes virus vectors for dendritic cells

Info

Publication number
IL141126A0
IL141126A0 IL14112699A IL14112699A IL141126A0 IL 141126 A0 IL141126 A0 IL 141126A0 IL 14112699 A IL14112699 A IL 14112699A IL 14112699 A IL14112699 A IL 14112699A IL 141126 A0 IL141126 A0 IL 141126A0
Authority
IL
Israel
Prior art keywords
herpes virus
dendritic cells
virus vectors
cell
virus
Prior art date
Application number
IL14112699A
Other languages
English (en)
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of IL141126A0 publication Critical patent/IL141126A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14112699A 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells IL141126A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816781.0A GB9816781D0 (en) 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells
PCT/GB1999/002529 WO2000008191A2 (fr) 1998-07-31 1999-08-02 Virus d'herpes destines aux cellules dendritiques

Publications (1)

Publication Number Publication Date
IL141126A0 true IL141126A0 (en) 2002-02-10

Family

ID=10836553

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14112699A IL141126A0 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells

Country Status (18)

Country Link
US (2) US6641817B1 (fr)
EP (1) EP1100942B1 (fr)
JP (1) JP4430824B2 (fr)
KR (1) KR100635246B1 (fr)
CN (1) CN1384884B (fr)
AT (1) ATE374829T1 (fr)
AU (1) AU765105B2 (fr)
BR (1) BR9912653A (fr)
CA (1) CA2337494C (fr)
CY (1) CY1107844T1 (fr)
DE (1) DE69937239T2 (fr)
DK (1) DK1100942T3 (fr)
ES (1) ES2294848T3 (fr)
GB (2) GB9816781D0 (fr)
HK (1) HK1037925A1 (fr)
IL (1) IL141126A0 (fr)
PT (1) PT1100942E (fr)
WO (1) WO2000008191A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
GB0009079D0 (en) * 2000-04-12 2000-05-31 Neurovex Ltd Herpes viruses for immune modulation
US6713067B2 (en) 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2001053505A2 (fr) 2000-01-21 2001-07-26 Biovex Limited Souches de virus herpetique
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
EP1406668A1 (fr) * 2001-05-02 2004-04-14 Ramot at Tel-Aviv University Ltd. Vecteurs du virus de l'herpes oncolytique composite
EP2213300B1 (fr) * 2001-05-09 2015-03-25 Takara Bio, Inc. Composition et procédé de traitement de cancer utilisant un virus herpétique
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US8216564B2 (en) 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
CA2421269A1 (fr) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methodes et compositions pour prolonger la duree de vie et accroitre la resistance au stress de cellules et d'organismes
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
KR100878017B1 (ko) * 2007-04-09 2009-01-14 인제대학교 산학협력단 이종 유전자 발현을 위한 숙주균 및 그의 이용방법
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
JP6342115B2 (ja) 2009-03-20 2018-06-13 メゾブラスト，インコーポレーテッド 再プログラム化多能性細胞の作製
CA2787628A1 (fr) 2010-01-21 2011-07-28 Dana-Farber Cancer Institute, Inc. Plate-forme de criblage genetique specifique du contexte pour assister la decouverte de genes et la validation de cibles
WO2012064743A2 (fr) 2010-11-08 2012-05-18 The Johns Hopkins University Procédés d'amélioration de la fonction cardiaque
US8969519B2 (en) 2011-09-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
WO2013055911A1 (fr) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Biomarqueur znf365/zfp365 pouvant prévoir une réponse anticancéreuse
EP3134546A4 (fr) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
CA2963091A1 (fr) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Biomarqueurs a base d'angiopoietine -2 utilises pour la prediction de la reponse de point de controle anti-immunitaire
JP6941561B2 (ja) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
AU2016229238B2 (en) 2015-03-06 2022-06-02 Dana-Farber Cancer Institute, Inc. PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
CA3002676A1 (fr) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Procedes pour identifier, evaluer, prevenir et traiter des troubles metaboliques au moyen de pm20d1 et d'acides amines n-lipides
CA3018332A1 (fr) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. Regulateurs de l'expression genique specifiques a l'etat d'epuisement des lymphocytes t et leurs utilisations
AU2017332721B2 (en) 2016-09-20 2023-11-09 Sara BUHRLAGE Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
CA3091960A1 (fr) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh Nouveau site d'insertion ul43 de l'herpesvirus equin
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP4343004A2 (fr) 2020-10-19 2024-03-27 Dana-Farber Cancer Institute, Inc. Biomarqueurs germinaux de réponse clinique et de bénéfice d'une thérapie par inhibiteur de point de contrôle immunitaire
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
EP4288140A1 (fr) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Traitement adjuvant du cancer
WO2022261183A2 (fr) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
WO2023097119A2 (fr) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
WO2023158732A1 (fr) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141574C (fr) * 1992-07-31 2009-11-24 David Knipe Vaccins contre l'herpesvirus
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation

Also Published As

Publication number Publication date
ATE374829T1 (de) 2007-10-15
EP1100942A2 (fr) 2001-05-23
GB0104400D0 (en) 2001-04-11
EP1100942B1 (fr) 2007-10-03
KR100635246B1 (ko) 2006-10-19
AU765105B2 (en) 2003-09-11
PT1100942E (pt) 2007-12-06
CN1384884B (zh) 2010-12-08
BR9912653A (pt) 2001-05-02
DE69937239T2 (de) 2008-07-24
DE69937239D1 (de) 2007-11-15
GB2361921B (en) 2003-12-17
CA2337494A1 (fr) 2000-02-17
AU5182299A (en) 2000-02-28
CY1107844T1 (el) 2013-06-19
JP2003502008A (ja) 2003-01-21
GB9816781D0 (en) 1998-09-30
WO2000008191A3 (fr) 2000-06-08
US20050249707A1 (en) 2005-11-10
HK1037925A1 (en) 2002-02-22
KR20010072162A (ko) 2001-07-31
ES2294848T3 (es) 2008-04-01
JP4430824B2 (ja) 2010-03-10
CA2337494C (fr) 2009-06-23
WO2000008191A2 (fr) 2000-02-17
GB2361921A (en) 2001-11-07
CN1384884A (zh) 2002-12-11
US6641817B1 (en) 2003-11-04
DK1100942T3 (da) 2008-02-04

Similar Documents

Publication Publication Date Title
GB2361921B (en) Herpes virus vectors for dendritic cells
ATE224442T1 (de) Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
GB2396227B (en) Method of and system for heuristically detecting viruses in executable code
EP0918848A4 (fr) Procedes de traitement de cancers et d'infections par pathogenes au moyen de cellules presentatrice d'antigenes chargees d'arn
EP1192948A3 (fr) Utilisation d'un mutant HSV dans le traitement du cancer
SE9604581D0 (sv) An agent against cancer and virus infections
GB2376687A (en) Herpes viruses for immune modulation
OA09653A (en) Rubella peptides
ZA914682B (en) Non-a non-b sequences
IL102915A0 (en) Soluble low density lipoprotein receptor and its preparation
WO1999013064A3 (fr) Infection virale de cellules
AU4733889A (en) 1-hydroxy-1,2,4-triazoles
Jeong et al. Site symmetry of Er sup 3 sup+ in In sub 0 sub. sub 5 Ga sub 0 sub. sub 5 P
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
UA32437C2 (uk) Спосіб здійснення експресії амінопептидазного антигену н110д
Burgos Jr We Forum, vol xix No. 12-July 17-23, 1995
Burgos Jr We Forum, vol xix No. 16-Aug. 14-20, 1995
Burgos Jr We Forum, vol xix No. 17-Aug. 21-27, 1995
MX9709514A (es) Viruses de fowlpox recombinantes y usos de los mismos.
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired